Immune-mediated and eosinophilic gastrointestinal disorders are increasingly recognized as important causes of chronic GI symptoms across all age groups. These conditions arise from dysregulated immune responses involving eosinophils, mast cells, and cytokine-mediated inflammation, often without overt structural abnormalities. Patients may present with abdominal pain, dysphagia, diarrhea, weight loss, or malnutrition. Advances in endoscopic techniques, histopathology, and molecular profiling have improved diagnostic accuracy. Management strategies include dietary interventions, pharmacologic immunomodulation, and emerging biologic therapies targeting specific inflammatory pathways. This topic highlights evolving insights into disease mechanisms, diagnostic challenges, and novel treatment approaches aimed at reducing inflammation and improving patient quality of life.
Title : Early and late evaluation of esophageal mucosectomy in surgical treatment of advanced esophageal achalasia
Jose Luis Braga De Aquino, Pontifical Catholic University of Campinas, Brazil
Title : How epigastric impedance would radically change gastric medicine
John Andrew Sutton, Invention City, United States
Title : Nanoemulsions as a strategy to enhance gastrointestinal bioavailability and bioactivity of lipid based nutraceuticals
Pubali Dhar, University of Calcutta, India
Title : Professional dining and health
Yaffa Machnes, Bar-Ilan University, Israel
Title : Sickle cell liver disease: A multidisciplinary hemato-hepatology approach
Bandar Aljudaibi, King Faisal Specialists Hospital and Research Centre, Saudi Arabia
Title : From the birth of atoms to life: Iodine and caesium, angels and demons of evolutionary biology, in pancreatic cancer and diabetes
Venturi Sebastiano, Department of Public Health of Romagna, Italy